Preparation and Characterization of Antibody Against Superbugs
Several monoclonal antibodies (mAbs) have been developed as alternatives or adjuvants to conventional antibiotics for the control of superbug infections. mAbs have relatively superior efficacy and tolerability in the treatment of drug-resistant bacteria. Despite this, some drug candidates have failed to pass clinical trials. The preparation and characterization process of antibodies is critical in order to obtain the desired efficacy and promising preclinical results.
Facing various development challenges, Ace Therapeutics has been working to advance the research and development of antibacterial mAbs. We provide a professional platform for the production and characterization of designed antibodies, using cutting-edge engineering techniques for mAb production to ensure the quality and efficacy of anti-superbug antibodies.
Some Anti-Bacterial Monoclonal Antibodies
There are currently three licensed antimicrobial monoclonal antibody drugs, with multiple candidates in preclinical or clinical stages. The licensed antibody drugs are primarily neutralizing bacterial exotoxins, targeting Bacillus anthracis and C. difficile. In addition to these, there are many drug candidates targeting typically drug-resistant gram-negative strains of bacteria such as drug-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and others. The types of drugs developed include antibody-antibiotic couples, antibody mixtures, etc.
Preparation and Characterization Services of Antibody Against Superbugs
In our service, a wide range of target-specific mAbs can be generated and characterized. The selection of those mAbs that exhibit good antibacterial activity against the targeted bacteria may be used to be developed into useful superbug therapeutics.
Fig. 1 Preparation and characterization process of anti-superbug monoclonal antibodies.
We offer cutting-edge engineering technologies for the production of mAb against drug-resistant bacteria, including but not limited to,
- Phage display antibody libraries
- Hybridoma technology
- Proteomics targeted cloning of serum mAb combined with high throughput sequencing technology
These advanced technologies have led to the development and production of antibodies to treat bacterial diseases that exhibit high levels of antibiotic resistance. The types of antibodies we can produce include,
- Antibody cocktails
- Bispecific antibodies
- Fc engineering
- Antibody-antibiotic conjugates
We discuss important characterizations of mAb-based therapies for the treatment of drug-resistant bacterial infections, including pharmacokinetic (PK) characteristics and pharmacodynamic (PD) mechanisms of action.
- PK characteristics. We help explore key PK considerations for antimicrobial mAb, including target-mediated drug disposition (TMDD) and mAb distribution in infected organs.
- PD mechanisms of action. The potential mechanisms of PD action are explored based on the nature of the target, its role in bacterial pathogenesis, and the mAb isotype and structure.
Our Highlights
Our technical support can help you make pathogen-specific antimicrobial mAb an attractive therapeutic option. They are expected to play a more prominent role in the future in the treatment of bacterial infections.
- Recent technological advances in antibody engineering, cell transfection techniques and other expression systems allow efficient production of anti-superbug mAb.
- Stable cell clone generation allows for preclinical development for mAb production.
- We significantly reduce production and characterization times and increase the likelihood of finding effective antibodies to treat superbug infections.
Ace Therapeutics will provide you with more production methods and in vitro studies bringing promising data, to establish monoclonal antibodies as a strategy for treatment or prevention against drug resistant bacteria. If you need more detailed information about our services, please contact us.
References
- Rossmann F S, et al. Isolation of highly active monoclonal antibodies against multiresistant gram-positive bacteria. PLoS One, 2015, 10(2): e0118405.
- Wang-Lin S X and Balthasar J P. Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections. Antibodies, 2018; 7(1): 5.